Final Results

RNS Number : 3661D
Judges Scientific PLC
28 March 2014
 

Judges Scientific plc

("Judges Scientific", "Judges", the "Company" or the "Group")

 

PRELIMINARY STATEMENT OF RESULTS FOR THE YEAR ENDED 31 DECEMBER 2013

Highlights:

·    Fully diluted earnings per share, excluding exceptional items, up 31% to 96.4p (2012: 73.5p)

·    Record basic earnings per share, excluding exceptional items, of 100.5p (2012: 81.3p);  corresponding figures including exceptional items: 23.4p (2012: 4.2p loss)

·    Proposed final dividend increased by 34% to 13.4p (2012: 10.0p), making a total distribution for the year of 20.0p (2012: 15.0p)

·    30% increase in pre-tax profit to a record £7.3 million (2012: £5.6 million) before exceptional items and non-controlling interests

·    Record revenues of £36.0 million (2012: £28.0 million), including a 4.3% increase on a like-for-like basis

·    Cash in hand of £10.1 million as at 31 December 2013;  adjusted net debt of £5.7 million (2012: £1.8 million)

·    Completion of the acquisition of Scientifica Limited, the Group's largest transaction to date

·    A substantially oversubscribed £8.1 million share placing at 1625p in October 2013.

 

Alex Hambro, Chairman of Judges Scientific, commented:

 

"The year 2013 was both exciting and rewarding, witnessing the completion of our largest acquisition to date and a substantially oversubscribed share placing.  A resilient operating performance, with a sizeable initial contribution from Scientifica, enabled the Group to generate earnings per share in a single year that exceeded our 2003 IPO price of 95p per share."

 

Chairman's Statement

 

I am pleased to be able to report, for the eighth consecutive year, record levels of sales, adjusted pre-tax profits, adjusted earnings per share and dividends.  Your Company enjoyed a successful year, which saw further corporate activity and a satisfactory trading performance achieved in a challenging economic environment.

 

Group revenues for the financial year ended 31 December 2013 advanced 28% from £28.0 million to £36.0 million.  This reflects organic growth of 4.3% plus a full year's contribution from Global Digital Systems Limited ("GDS" - ten months in 2012) and a maiden six-month contribution from Scientifica Limited ("Scientifica").

 

Profit before tax, exceptional items and minorities increased by 30% to a record £7.3 million (2012: £5.6 million), with the operating contribution of the businesses owned as at 1 January 2012 growing by 13.8%.  Basic earnings per share, before exceptional items, rose by 23.6% from 81.3p to 100.5p.  This increase was achieved despite the dilution created by the 2012 and 2013 share placings and the conversion in 2012 of almost all of the Convertible Redeemable shares.  Only 4.2% of the original Convertible Redeemable shares now remain outstanding. Fully diluted earnings per share, before exceptional items, progressed 31.2% to 96.4p (2012: 73.5p).

 

Exceptional items include the amortisation of intangible assets, acquisition expenses, tax relief arising from the issue of shares to employees and other non-trading items as set out in the Income Statement. The accounting "loss" attributable to the few remaining Convertible Redeemable shares was reduced to £340,000 (2012: £1.6 million);  this adjustment is expected to appear for the last time in 2014.  Profit, including exceptional items but before tax and minorities, amounted to £1.2 million (2012: £321,000).  Including exceptional items, basic earnings per share amounted to 23.4p (2012: 4.2p loss) while fully diluted earnings per share totalled 22.5p (2012: 4.2p loss).

 

Corporate activity

 

On 26 June 2013, Judges acquired the entire share capital of Scientifica, a leading specialist in the design and manufacture of systems used in neuroscience research.  The consideration amounted to £12.0 million in cash and an earn-out capped at £500,000 in cash and 42,372 Ordinary shares in Judges. The earn-out is based on Scientifica's financial performance in respect of the 12 month period to 31 March 2014.  The acquisition was financed by an extension of the facilities provided by Lloyds Bank Corporate Markets and from existing cash resources.

 

In October 2013, the Company restored its ability to complete further acquisitions by raising new equity of £8.125 million before expenses. This was achieved through a placing of 500,000 new Ordinary shares priced at 1625p, which was substantially over-subscribed.  In the main, the new Ordinary shares were placed with existing and several new institutional holders.

 

Trading in 2013

 

In common with many companies operating within our sector, the year under review proved distinctly challenging.  Despite a promising start, the Company experienced weak order intake, particularly during the second quarter of the year.  A gradual improvement as the year progressed culminated in an excellent fourth quarter.  I am pleased to report that this leaves the Group with a comfortable year-end order book of ten and a half weeks of budgeted sales.

 

Supported by a healthy order book at the beginning of 2013 and thanks in part to the diversity of the markets that we serve, the Group produced 4.3% organic growth in revenues.  This encompassed a modest reduction in North America, but a solid advance in Europe.  The respective revenues of GDS and Scientifica, both of which have increased strongly post acquisition, are not included in the figures for organic growth, these companies having been acquired after January 2012.

 

As highlighted in previous annual reports, the inevitable consequence of a large acquisition at a multiple of six times EBIT is to reduce the Company's Return On Total Invested Capital;  this was again the case with Scientifica which served to reduce ROTIC from 40.3% in 2012 to 30.2% in 2013.

 

The development of the Stonecross factory was completed in the summer of 2013 and the UHV Design and Quorum businesses were successfully re-located into the new facility in August.  Your Board expects these businesses to derive significant benefits during the current financial year and beyond from operating in this purpose-built unit.

 

Financial position

 

Net debt as at 31 December 2013 stood at £5.5 million;  excluding subordinated debt owed to minority shareholders but including cash amounts still payable in respect of acquisitions, this figure rises to £5.7 million (2012: £1.7 million).  The Group's cash position during the year reflected £12.4 million of net debt taken on to purchase Scientifica, £1.8 million spent in 2013 to complete the Stonecross factory and the net proceeds from the share placing.

 

Year-end cash balances progressed from £5.4 million to £10.1 million.

 

Dividends

 

Your Board is pleased to recommend a final dividend of 13.4p per share (2012: 10p per share) which, subject to approval at the forthcoming Annual General Meeting on 28 May 2014, will make a total distribution of 20.0p per share in respect of 2013 (2012: 15.0p per share).  Despite the proposed increase, the dividend total is still covered five times by adjusted earnings per share.

 

The proposed final dividend will be payable on 4 July 2014 to shareholders on the register on 6 June 2014 and the shares will go ex-dividend on 4 June 2014.

 

Personnel

 

The Judges Share Incentive Plan was launched in 2012 to enable all employees with a minimum of 12 months' service to purchase shares in a tax efficient manner.  In the coming tax year, the Company will continue to match individual employees' investments with free shares, up to a maximum value of £600.

 

The addition of Scientifica brings our total number of Group employees to more than 260 at the end of 2013.  Each company within the Group has, in its own way, demonstrated resilience and dedication to its particular plans and the enthusiasm and energy of our stakeholders is the primary reason why this year's results have been so gratifying.  Our thanks go to them and all the executive management for their continued commitment to Judges' future trajectory.

 

Current trading and prospects

 

Commercial activity in the early weeks of 2014 was sedate but, following the buoyant final quarter of the previous year, the Group continues to enjoy a robust order book.  As in the past we are conscious of the potential impact of Sterling strengthening and of the Chinese economy weakening.  Our export driven business should benefit from the best climate in the developed world since 2008 and it is hoped that it will not be spoilt by the political tensions playing out on the world stage.

 

 

 

Alex Hambro

Chairman

 

 

 

For further information please contact:

Judges Scientific plc

David Cicurel, CEO

Tel: 01342 323 600

 

Shore Capital (Nominated Adviser & Broker)

Pascal Keane

Edward Mansfield

Tel: 020 7408 4090

 

Cardew Group (Financial Public Relations)

Melvyn Marckus

Tel: 0207 930 0777 or 07775 896 491

 



 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 





2013




2012


Note

Before exceptional items

Exceptional items

Total


Before exceptional items

Exceptional items

Total



£000

£000

£000


£000

£000

£000










Revenue

2

36,041

-

36,041


28,041

-

28,041










Operating costs excluding exceptional items


(28,228)

-

(28,228)


(22,097)

-

(22,097)










Operating profit excluding exceptional items


7,813

-

7,813


-

5,944










Exceptional items









Amortisation of intangible assets


-

(4,498)

(4,498)


-

(3,294)

(3,294)

Contingent consideration measured at fair value


-

(317)

(317)


-

-

-

Financial instruments measured at fair value









Convertible Redeemable shares


-

(340)

(340)


-

(1,573)

(1,573)

Hedging contracts


-

24

24


-

-

-

Relocation costs


-

(158)

(158)


-

-

-

Acquisition costs


-

(794)

(794)


-

(444)

(444)










Operating profit/(loss)


7,813

(6,083)

1,730


(5,311)

633










Interest receivable


6

-

6


7

-

7

Interest payable


(497)

-

(497)


(319)

-

(319)










Profit/(loss) before tax


7,322

(6,083)

1,239


(5,311)

321










Taxation


(1,530)

1,632

102


(1,302)

850

(452)










Profit/(loss) and total comprehensive income for the year


5,792

(4,451)

1,341


4,330

(4,461)

(131)









Attributable to:


















Equity holders of the parent company


5,444

(4,178)

1,266


3,887

(4,087)

(200)

Non-controlling interest


348

(273)

75


443

(374)

69









Earnings per share - total and continuing









Basic

1

100.5p

-

23.4p


81.3p

-

(4.2)p

Diluted

1

96.4p

-

22.5p


73.5p

-

(4.2)p

 



 

CONSOLIDATED BALANCE SHEET

AS AT 31 DECEMBER 2013

 

 

 



2013


2012







Note

£000


£000

ASSETS





Non-current assets





Property, plant and equipment


4,695


2,702

Goodwill


8,678


5,809

Other intangible assets


12,913


7,095



26,286


15,606

Current assets





Inventories


5,824


3,529

Trade and other receivables


6,547


3,988

Cash and cash equivalents


10,054


5,418



22,425


12,935






Total assets


48,711


28,541






LIABILITIES





Current liabilities





Trade and other payables


(6,075)


(5,659)

Derivative financial instruments:  Convertible Redeemable shares


(574)


(234)

Payables relating to acquisitions


(1,554)


(246)

Current portion of long-term borrowings

3

(4,043)


(2,028)

Current tax payable


(1,320)


(633)



(13,566)


(8,800)

Non-current liabilities





Long-term borrowings

3

(11,547)


(5,390)

Deferred tax liabilities


(2,704)


(1,562)



(14,251)


(6,952)






Total liabilities


(27,817)


(15,752)






Net assets


20,894


12,789

 

EQUITY





Share capital


293


265

Share premium account


14,186


6,467

Capital redemption reserve


22


22

Merger reserve


475


475

Retained earnings


5,635


5,254

Equity attributable to equity holders of the parent company


20,611


12,483






Non-controlling interest


283


306






Total equity


20,894


12,789

 



 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 



Share capital

Share premium

Capital redemption reserve

Merger reserve

Retained earnings

Total*

Non-controlling interest

Total equity



£000

£000

£000

£000

£000

£000

£000

£000











Balance at

1 January 2013


265

6,467

22

475

5,254

12,483

306

12,789

Dividends


-

-

-

-

(885)

(885)

(98)

(983)

Issue of share capital


28

7,719

-

-

-

7,747

-

7,747

Transactions with owners


28

7,719

-

-

(885)

6,862

(98)

6,764

Profit for the year


-

-

-

-

1,266

1,266

75

1,341

Total comprehensive income for the year


-

-

-

-

1,266

1,266

75

1,341

Balance at 31 December 2013


293

14,186

22

475

5,635

20,611

283

20,894











Balance at

1 January 2012


214

3,195

3

475

3,489

7,376

335

7,711

Dividends


-

-

-

-

(587)

(587)

(98)

(685)

Issue of share capital


51

3,272

-

-

-

3,323

-

3,323

Arising on conversion and redemption of Convertible Redeemable shares


-

-

19

-

2,552

2,571

-

2,571

Transactions with owners


51

3,272

19

-

1,965

5,307

(98)

5,209

(Loss)/profit for the year


-

-

-

-

(200)

(200)

69

(131)

Total comprehensive income for the year


-

-

-

-

(200)

(200)

69

(131)

Balance at 31 December 2012


265

6,467

22

475

5,254

12,483

306

12,789

 

 

 

* - Total represents amounts attributable to equity holders of the parent company.



 

CONSOLIDATED CASH FLOW STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 



2013


2012



£000


£000

Cash flows from operating activities





Profit/(loss) after tax


1,341


(131)

Adjustments for:





Financial instruments measured at fair value





Convertible Redeemable shares


340


1,573

Hedging contracts


(24)


-

Contingent consideration measured at fair value


317


-

Depreciation


292


235

Amortisation of intangible assets


4,498


3,294

Loss on disposal of property, plant and equipment


18


-

Foreign exchange loss/(gain) on foreign currency loans


127


(78)

Interest receivable


(6)


(7)

Interest payable


497


319

Tax expense recognised in income statement


(102)


452

Increase in inventories


(783)


(581)

(Increase)/decrease in trade and other receivables


(798)


277

(Decrease)/increase in trade and other payables


(709)


1,007

Cash generated from operations


5,008


6,360

Interest paid


(497)


(324)

Tax paid


(840)


(1,374)

Net cash from operating activities


3,671


4,662






Cash flows from investing activities





Paid on acquisition of new subsidiary


(13,400)


(8,022)

Gross cash inherited on acquisition


1,772


1,378

Acquisition of subsidiaries, net of cash acquired


(11,628)


(6,644)

Paid on the acquisition of trade and certain assets


(91)


(94)

Purchase of property, plant and equipment


(2,080)


(909)

Interest received


6


7

Net cash used in investing activities


(13,793)


(7,640)






Cash flows from financing activities





Proceeds from issue of share capital


7,747


3,323

Repaid on conversion/redemption of Convertible Redeemable shares


-


(516)

Repayments of borrowings


(1,776)


(3,155)

Proceeds from bank loans


9,770


5,475

Dividends paid - equity share holders


(885)


(587)

Dividends paid - non-controlling interest in subsidiary


(98)


(98)

Net cash from financing activities


14,758


4,442






Net increase in cash and cash equivalents


4,636


1,464

Cash and cash equivalents at beginning of year


5,418


3,954






Cash and cash equivalents at end of year


10,054


5,418



 

NOTES TO THE PRELIMINARY ANNOUNCEMENT

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 

1.         Earnings per share

 


Year to 31 December 2013

Earnings

attributable

to equity

holders of

the parent

company

Weighted

average

number of

shares

Earnings

per

share



£000

no.

pence







Profit after tax including exceptional items for calculation of basic and diluted earnings per share

1,266




Add-back exceptional items net of tax and non-controlling interest, as applicable:





Charge relating to derivative financial instruments





Hedging contracts

(18)




Convertible Redeemable shares

340




Contingent consideration measured at fair value

317




Tax relief on exercise of share options

(154)




Amortisation of intangible assets

2,897




Acquisition-related transactions costs

716




Relocation costs

120




Utilisation of prior year tax losses

(40)




Basic and diluted profit after tax, excluding exceptional items

5,444









Number of shares for calculation of basic earnings per share including exceptional items


5,417,971



Effect of potential shares


201,205



Number of shares for calculation of diluted earnings per share including exceptional items


5,619,176



Dilutive effect of potential derivative financial instruments


26,068



Number of shares for calculation of diluted earnings per share excluding exceptional items


5,645,244








Basic earnings per share (including exceptional items)



23.4


Diluted earnings per share (including exceptional items)



22.5


Basic earnings per share (excluding exceptional items)



100.5


Diluted earnings per share (excluding exceptional items)



96.4

 



NOTES TO THE PRELIMINARY ANNOUNCEMENT

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 

1.         Earnings per share (continued)

 


Year to 31 December 2012

Earnings

attributable

to equity

holders of

the parent

company

Weighted

average

number of

shares

Earnings

per

share



£000

no.

pence







Loss after tax including exceptional items for calculation of basic and diluted earnings per share

(200)




Add-back exceptional items net of tax and non-controlling interest, as applicable:





Charge relating to derivative financial instruments





Convertible Redeemable shares

1,895




Tax relief on exercise of share options

(133)




Amortisation of intangible assets

1,972




Acquisition-related transactions costs

358




Utilisation of prior year tax losses

(5)




Basic and diluted profit after tax, excluding exceptional items

3,887









Number of shares for calculation of basic earnings per share including exceptional items


4,780,562



Effect of potential shares


209,208



Number of shares for calculation of diluted earnings per share including exceptional items


4,989,770



Dilutive effect of potential derivative financial instruments


299,106



Number of shares for calculation of diluted earnings per share excluding exceptional items


5,288,876








Basic earnings per share (including exceptional items)



(4.2)


Diluted earnings per share (including exceptional items)



(4.2)


Basic earnings per share (excluding exceptional items)



81.3


Diluted earnings per share (excluding exceptional items)



73.5

 



NOTES TO THE PRELIMINARY ANNOUNCEMENT

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 

2.         Segment analysis

 

2013

Materials Sciences

Vacuum

Total


£000

£000

£000

Consolidated group revenues from external customers

14,764

21,277

36,041

Contributions to group EBITA

3,710

4,631

8,341

Depreciation

91

177

268

Amortisation of intangible assets

1,647

2,851

4,498

Segment assets

7,375

13,234

20,609

Segment liabilities

5,009

21,225

26,234

Intangible assets - goodwill

5,156

3,522

8,678

Other intangible assets

4,156

8,757

12,913

Additions to non-current assets

39

13,647

13,686

 

2012

Materials Sciences

Vacuum

Total


£000

£000

£000

Consolidated group revenues from external customers

12,949

15,092

28,041

Contributions to group EBITA

3,448

2,700

6,148

Depreciation

72

155

227

Amortisation of intangible assets

2,184

1,110

3,294

Segment assets

6,141

6,273

12,414

Segment liabilities

3,180

5,764

8,944

Intangible assets - goodwill

5,157

652

5,809

Other intangible assets

5,802

1,293

7,095

Additions to non-current assets

8,740

174

8,914

 

Segmental revenue is presented on the basis of the destination of the goods where known, failing which on the geographical location of customers.  Segment assets are based on the geographical location of assets.

 


2013


2012


Revenue

Non-current assets


Revenue

Non-current assets


£000

£000


£000

£000







United Kingdom (domicile)

6,680

26,286


3,517

15,606

Rest of Europe

11,434

-


9,375

-

United States/Canada

6,055

-


4,434

-

Rest of the world

11,872

-


10,715

-

Total

36,041

26,286


28,041

15,606

NOTES TO THE PRELIMINARY ANNOUNCEMENT

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 

3.         Maturity of borrowings and net debt

 


31 December 2013

Bank loan

Subordinated

Total




loans




£000

£000

£000







Repayable in less than 6 months

2,069

497

2,566


Repayable in months 7 to 12

2,036

-

2,036


Current portion of long-term borrowings

4,105

497

4,602


Repayable in years 1 to 5

12,331

-

12,331


Later than 5 years

11

-

11


Total borrowings

16,447

497

16,944







Less:  interest included above

1,405

-

1,405


cash and cash equivalents

10,054

-

10,054


Total net debt

4,988

497

5,485

 

In addition, hire purchase debts amounted to £51,000.

 


31 December 2012

Bank loan

Subordinated

Total




loans




£000

£000

£000







Repayable in less than 6 months

934

497

1,431


Repayable in months 7 to 12

919

-

919


Current portion of long-term borrowings

1,853

497

2,350


Repayable in years 1 to 5

5,832

-

5,832


Later than 5 years

59

-

59


Total borrowings

7,744

497

8,241







Less:  interest included above

823

-

823


cash and cash equivalents

5,418

-

5,418


Total net debt

1,503

497

2,000

 



NOTES TO THE PRELIMINARY ANNOUNCEMENT

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 

4.         Acquisition of Scientifica Limited

 

On 26 June 2013 the Company's wholly owned subsidiary, Judges Capital Limited, acquired the entire issued share capital of Scientifica Limited ("Scientifica"), a company based in the UK.  The total cost of acquisition included the components stated below.

 

Consideration

£000



Initial cash payment to vendors

12,000

Contingent consideration - fair value at date of acquisition

1,047


13,047

Gross cash inherited on acquisition

1,772

Cash retained in the business

(372)

Payment to vendors in respect of surplus working capital

1,400

Total consideration transferred

14,447



Acquisition-related transaction costs charged in the income statement

794

 

Additional contingent consideration will be payable on an incremental basis in the event that Scientifica generates higher operating profits in the twelve months period to 31 March 2014 than those calculated in the prior year in accordance with the sale and purchase agreement.  The maximum value of additional contingent consideration will be achieved if operating profits of £2.167m are generated in this period and would bring the total consideration to £12.5 million in cash, 42,372 Ordinary shares in Judges Scientific plc and a payment of £1.4 million to reflect excess working capital at the time of the acquisition.

 



 

NOTES TO THE PRELIMINARY ANNOUNCEMENT

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 

4.         Acquisition of Scientifica Limited (continued)

 

The amounts recognised for each class of the acquiree's assets, liabilities and contingent liabilities at the acquisition date are as follows:

 


Pre-acquisition carrying amount

Adjustment to fair value

Recognised at acquisition date


£000

£000

£000





Property, plant and equipment

223

-

223

Intangible assets

-

10,316

10,316

Inventories

1,512

-

1,512

Trade and other receivables

1,738

-

1,738

Cash and cash equivalents

1,772

-

1,772

Total assets

5,245

10,316

15,561

Deferred tax liabilities

(48)

(2,372)

(2,421)

Trade payables

(1,212)

-

(1,212)

Current tax liability

(351)

-

(351)

Total liabilities

(1,611)

(2,372)

(3,983)

Net identifiable assets and liabilities

3,634

7,944

11,578

Goodwill arising on acquisition

2,869

Total cost of acquisition

14,447

 

 

5.         Preliminary Announcement

 

This preliminary announcement, which has been agreed with the auditors, was approved by the board of directors on 27 March 2014.  It is not the group's statutory accounts.  Copies of the group's audited statutory accounts for the year ended 31 December 2013 will be available at the company's website, www.judges.uk.com, promptly after the release of this preliminary announcement and a printed version will be dispatched to shareholders shortly.  Copies will also be available to the public at the company's Registered Office at Unit 19, Charlwoods Road, East Grinstead, West Sussex RH19 2HL.

 

The audit reports for the years ended 31 December 2013 and 31 December 2012 did not contain statements under Sections 498(2) or 498(3) of the Companies Act 2006.  The statutory accounts for the year ended 31 December 2012 have been delivered to the Registrar of Companies, but the 31 December 2013 accounts have not yet been filed.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR SESFDWFLSEID
UK 100

Latest directors dealings